HK1257499A1 - 用於治療的聚集性微粒 - Google Patents

用於治療的聚集性微粒

Info

Publication number
HK1257499A1
HK1257499A1 HK18116289.6A HK18116289A HK1257499A1 HK 1257499 A1 HK1257499 A1 HK 1257499A1 HK 18116289 A HK18116289 A HK 18116289A HK 1257499 A1 HK1257499 A1 HK 1257499A1
Authority
HK
Hong Kong
Prior art keywords
therapy
aggregating microparticles
aggregating
microparticles
Prior art date
Application number
HK18116289.6A
Other languages
English (en)
Inventor
Yun Yu
Joshua Kays
Ming Yang
Jeffrey L Cleland
Original Assignee
Graybug Vision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Graybug Vision Inc filed Critical Graybug Vision Inc
Publication of HK1257499A1 publication Critical patent/HK1257499A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)
HK18116289.6A 2015-11-12 2018-12-19 用於治療的聚集性微粒 HK1257499A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562254707P 2015-11-12 2015-11-12
US201562257608P 2015-11-19 2015-11-19
US201662276530P 2016-01-08 2016-01-08
PCT/US2016/061706 WO2017083779A1 (en) 2015-11-12 2016-11-11 Aggregating microparticles for therapy

Publications (1)

Publication Number Publication Date
HK1257499A1 true HK1257499A1 (zh) 2019-10-25

Family

ID=58690442

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18116289.6A HK1257499A1 (zh) 2015-11-12 2018-12-19 用於治療的聚集性微粒

Country Status (15)

Country Link
US (4) US10441548B2 (zh)
EP (1) EP3373978A4 (zh)
JP (2) JP2018533596A (zh)
KR (1) KR20180102069A (zh)
CN (2) CN114469872A (zh)
AU (1) AU2016353355B9 (zh)
BR (1) BR112018009644A2 (zh)
CA (1) CA3004886A1 (zh)
EA (1) EA038755B1 (zh)
HK (1) HK1257499A1 (zh)
IL (1) IL259167A (zh)
MX (1) MX2018005932A (zh)
PH (1) PH12018500905A1 (zh)
SG (1) SG11201803663XA (zh)
WO (1) WO2017083779A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018128876A1 (en) * 2017-01-03 2018-07-12 Vitrean, Inc. Methods and devices for treating a retinal detachment
MX2019013363A (es) * 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
JP2021522224A (ja) * 2018-04-23 2021-08-30 グレイバグ ビジョン インコーポレイテッド 改善された連続式のマイクロ粒子の製造
WO2020102758A1 (en) * 2018-11-15 2020-05-22 Graybug Vision, Inc. Improved aggregated microparticles
KR102039582B1 (ko) * 2018-12-12 2019-11-01 주식회사 라파스 인장 공정으로 제조하기에 적합한 마이크로니들 재료의 적합성 시험 방법 및 이를 포함하는 마이크로니들 제조 방법
WO2021224999A1 (ja) * 2020-05-08 2021-11-11 エム・テクニック株式会社 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤
ES2967667T3 (es) 2020-06-11 2024-05-03 Univ Internacional De Catalunya Fundacio Privada Composición que comprende nanopartículas, método para la preparación de una composición que comprende nanopartículas y usos de la composición para tratamiento dental
US20240197635A1 (en) * 2021-03-03 2024-06-20 Veramorph Llc Dissociating polymer matrix compositions of fulvestrant and methods of their making and use
US20240189277A1 (en) * 2021-04-16 2024-06-13 The Johns Hopkins University Ophthalmic formulations for sustained neuroprotection
CN113350268B (zh) * 2021-06-17 2023-09-05 复旦大学附属眼耳鼻喉科医院 一种用于眼结膜下植入的药物缓释凝胶及其制备方法
CN113577083B (zh) * 2021-08-13 2022-07-05 中山大学中山眼科中心 一种小分子化合物组合在制备预防和治疗视网膜损伤性疾病药物中的应用
CN114773220B (zh) * 2021-12-21 2024-01-26 西安阿伯塔资环分析测试技术有限公司 一种刚性双尾表面活性剂及其制备方法和清洁压裂液
WO2024037982A1 (en) 2022-08-16 2024-02-22 Boehringer Ingelheim International Gmbh Pharmaceutical formulations of nintedanib for intraocular use
WO2024074585A2 (en) 2022-10-05 2024-04-11 Mireca Medicines Gmbh MICROPARTICLE AND IMPLANT FORMULATIONS FOR cGMP ANALOG THERAPY
WO2024148131A1 (en) * 2023-01-06 2024-07-11 The Johns Hopkins University Organic solvent free drug microcrystals
WO2024151628A1 (en) * 2023-01-09 2024-07-18 The General Hospital Corporation Polymeric microparticles encapsulated with active pharmaceutical ingredients and related methods of use and manufacture
CN116637069B (zh) * 2023-07-19 2023-09-19 成都金瑞基业生物科技有限公司 一种和厚朴酚脂质体透皮凝胶剂及其制备方法和应用

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB929405A (en) 1958-12-22 1963-06-19 Upjohn Co Processes for the encapsulation of particles
GB929401A (en) 1958-12-22 1963-06-19 Upjohn Co Encapsulated emulsions and processes for their preparation
IT1148784B (it) 1980-04-09 1986-12-03 Eurand Spa Procedimento per la preparazione di microcapsule in un veicolo liquido
US4760057A (en) 1983-06-23 1988-07-26 Merck & Co., Inc. (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US4997443A (en) 1985-08-26 1991-03-05 Hana Biologics, Inc. Transplantable artificial tissue and process
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5843156A (en) 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5286495A (en) 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
US5344701A (en) 1992-06-09 1994-09-06 Minnesota Mining And Manufacturing Company Porous supports having azlactone-functional surfaces
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5502092A (en) 1994-02-18 1996-03-26 Minnesota Mining And Manufacturing Company Biocompatible porous matrix of bioabsorbable material
US5441722A (en) 1994-02-18 1995-08-15 Merck & Co., Inc. Short synthesis of 5,6-dihydro-(S)-4-(ethylamino)-(S)-6-[C3 H3 ]-4[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide and related non radioactive compounds
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
EP0805678B1 (en) 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Surface-modified nanoparticles and method of making and using same
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US6413539B1 (en) 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US6129761A (en) 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5916586A (en) 1995-08-24 1999-06-29 Lever Brothers Company, Inc. Personal cleansing system comprising polymeric diamond-mesh bath sponge and liquid cleanser with deodorant composition
US5855615A (en) 1996-06-07 1999-01-05 Menlo Care, Inc. Controller expansion sphincter augmentation media
US6566406B1 (en) 1998-12-04 2003-05-20 Incept, Llc Biocompatible crosslinked polymers
US5866155A (en) 1996-11-20 1999-02-02 Allegheny Health, Education And Research Foundation Methods for using microsphere polymers in bone replacement matrices and composition produced thereby
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
GB9704749D0 (en) 1997-03-07 1997-04-23 Univ London Tissue Implant
GB9713980D0 (en) 1997-07-03 1997-09-10 Danbiosyst Uk New conjugates
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
CA2221195A1 (en) 1997-11-14 1999-05-14 Chantal E. Holy Biodegradable polymer matrix
US6841617B2 (en) 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
US6632457B1 (en) 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6703047B2 (en) 2001-02-02 2004-03-09 Incept Llc Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use
US6818018B1 (en) 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US20040258763A1 (en) 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
IN192012B (zh) 1999-03-19 2004-02-07 Vinod Chintamani Malshe
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
EP1173517A4 (en) 1999-04-26 2006-06-28 California Inst Of Techn HYDROGELS CONSTITUTING IN SITU
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6333029B1 (en) 1999-06-30 2001-12-25 Ethicon, Inc. Porous tissue scaffoldings for the repair of regeneration of tissue
SE9904344D0 (sv) 1999-12-01 1999-12-01 Ralf Goeran Andersson Method of producing porous spherical particles
DE122010000004I1 (de) 2000-02-15 2010-04-15 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
ATE537845T1 (de) 2000-10-31 2012-01-15 Pr Pharmaceuticals Inc Verfahren zur herstellung von formulierungen zur verbesserten abgabe von bioaktiven molekülen
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB2370839A (en) 2001-01-06 2002-07-10 Benedikt Timmerman Immunogenic complex useful for disease control
BR0102252B1 (pt) 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
US20020183858A1 (en) 2001-06-05 2002-12-05 Contiliano Joseph H. Attachment of absorbable tissue scaffolds to scaffold fixation devices
JP4758607B2 (ja) 2001-06-22 2011-08-31 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン 生分解性ポリマー組成物、及びその使用方法
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
MXPA05002669A (es) 2002-09-13 2005-08-19 Ocular Sciences Inc Dispositivos y metodos para mejorar la vision.
MXPA05003183A (es) * 2002-09-26 2005-06-08 Angiotech Int Ag Evolturas perivasculares.
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
AU2003299722A1 (en) 2002-12-17 2004-07-14 Mdrna, Inc. Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
US7060299B2 (en) 2002-12-31 2006-06-13 Battelle Memorial Institute Biodegradable microparticles that stabilize and control the release of proteins
GB0307011D0 (en) 2003-03-27 2003-04-30 Regentec Ltd Porous matrix
TWI377958B (en) 2003-06-26 2012-12-01 Control Delivery Sys Inc In-situ gelling drug delivery system
JP5628467B2 (ja) 2003-06-26 2014-11-19 シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． 生体分解性徐放性ドラッグデリバリーシステム
JP2008518881A (ja) 2003-07-18 2008-06-05 オークウッド ラボラトリーズ，エル．エル．シー． 高分子組成物中の高分子の分子量低下、不純物形成およびゲル化の防止
WO2005014524A2 (en) 2003-08-07 2005-02-17 Wisconsin Alumni Research Foundation Amino thiol compounds and compositions for use in conjunction with cancer therapy
US20090148527A1 (en) 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20050175709A1 (en) 2003-12-11 2005-08-11 Baty Ace M.Iii Therapeutic microparticles
WO2005072125A2 (en) 2004-01-16 2005-08-11 Massachusetts Institute Of Technology Composite materials for controlled release of water soluble products
US8957034B2 (en) 2004-01-28 2015-02-17 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8163030B2 (en) 2004-05-06 2012-04-24 Degradable Solutions Ag Biocompatible bone implant compositions and methods for repairing a bone defect
WO2005116729A2 (en) 2004-05-20 2005-12-08 Coopervision, Inc., Corneal onlays and wavefront aberration correction to enhance vision
WO2006044660A2 (en) 2004-10-14 2006-04-27 Vanderbilt University Functionalized solid lipid nanoparticles and methods of making and using same
WO2006060723A2 (en) 2004-12-03 2006-06-08 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
CA2605560A1 (en) 2005-04-22 2006-11-02 Kristen Hjortsvang Immunoliposome composition for targeting to a her2 cell receptor
MX2007013356A (es) 2005-04-27 2008-03-26 Baxter Int Microparticulas modificadas en la superficie y metodos de formacion y uso de las mismas.
MX2007016050A (es) 2005-06-17 2008-03-10 Australian Nuclear Science Tec Particulas que comprenden un dopante que se puede liberar en las mismas.
EP1959966B1 (en) 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolone formulations and methods for the making and use thereof
DE102005058979A1 (de) 2005-12-09 2007-06-21 Qiagen Gmbh Magnetische Polymerpartikel
WO2007068489A2 (en) 2005-12-14 2007-06-21 Scil Technology Gmbh A moldable biomaterial for bone regeneration
US7501179B2 (en) 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
WO2007076358A1 (en) 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CA2636716C (en) 2006-01-13 2014-12-23 Surmodics, Inc. Microparticle containing matrices for drug delivery
US20070231360A1 (en) 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
US20080166411A1 (en) 2006-04-10 2008-07-10 Pfizer Inc Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
US7883520B2 (en) 2006-04-10 2011-02-08 Forsight Labs, Llc Corneal epithelial pocket formation systems, components and methods
CN101081296B (zh) 2006-05-29 2010-08-04 北京民海生物科技有限公司 一种b型流感嗜血杆菌荚膜多糖制备方法及其联合疫苗
EP1891941A1 (en) 2006-08-11 2008-02-27 OctoPlus Technologies B.V. Aqueous gels comprising microspheres
DE602007012559D1 (de) 2006-09-08 2011-03-31 Univ Johns Hopkins H die schleimhaut
US7998108B2 (en) 2006-09-12 2011-08-16 Psivida Us, Inc. Injector apparatus and method of use
GB0619869D0 (en) 2006-10-07 2006-11-15 Regentec Ltd Porous particles
EP2409687B1 (en) 2006-11-09 2014-06-11 Alcon Research, Ltd. Water insoluble polymer matrix for drug delivery
GB0701896D0 (en) 2007-02-01 2007-03-14 Regentec Ltd Composition
JP2010519183A (ja) 2007-02-06 2010-06-03 インセプト エルエルシー 生理溶液の溶出のためのタンパク質の沈殿を用いる重合
WO2008112287A1 (en) 2007-03-12 2008-09-18 Nektar Therapeutics Oligomer-beta blocker conjugates
US8492334B2 (en) 2007-06-21 2013-07-23 Yale University Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
CN101081206A (zh) 2007-06-29 2007-12-05 济南康泉医药科技有限公司 一种含酪氨酸激酶抑制剂的抗癌药物组合物
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
WO2009035565A1 (en) 2007-09-07 2009-03-19 Qlt Plug Delivery, Inc Prostaglandin analogues for implant devices and methods
CN101873869A (zh) * 2007-10-26 2010-10-27 国家免疫学研究所 可生物降解的聚合物支架及其制备方法
US8414646B2 (en) 2007-12-27 2013-04-09 Forsight Labs, Llc Intraocular, accommodating lens and methods of use
EP2237744B1 (en) 2008-01-03 2018-04-04 Forsight Labs, Llc Intraocular accommodating lens.
WO2009089070A2 (en) 2008-01-10 2009-07-16 The Johns Hopkins University Compositions and methods for reducing particle penetration through mucus
US20090203709A1 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
CA2717133C (en) 2008-02-29 2016-04-26 Nagoya Industrial Science Research Institute Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye
US9125735B2 (en) 2008-04-04 2015-09-08 Forsight Labs, Llc Method of correcting vision using corneal onlays
WO2009132265A2 (en) 2008-04-25 2009-10-29 The University Of North Carolina At Chapel Hill Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates
US20110206773A1 (en) 2008-05-20 2011-08-25 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
US8993615B2 (en) 2008-08-08 2015-03-31 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
TW201019963A (en) 2008-09-10 2010-06-01 Abbott Lab Polyethylene glycol lipid conjugates and uses thereof
US9161903B2 (en) 2008-10-31 2015-10-20 Warsaw Orthopedic, Inc. Flowable composition that hardens on delivery to a target tissue site beneath the skin
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100143479A1 (en) 2008-12-04 2010-06-10 Oakwood Laboratories, Llc Method of making sustained release microparticles
WO2010079496A2 (en) 2009-01-12 2010-07-15 Hadasit Medical Research Services & Development Limited Tissue regeneration membrane
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CN104887389B (zh) 2009-01-29 2017-06-23 弗赛特影像4股份有限公司 后段给药
WO2010091187A2 (en) 2009-02-04 2010-08-12 The Brigham And Women's Hospital, Inc. Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
US8192408B2 (en) 2009-02-10 2012-06-05 Psivida Us, Inc. Ocular trocar assembly
CA2750242C (en) 2009-02-12 2018-05-22 Incept, Llc Drug delivery through hydrogel plugs
ES2508290T3 (es) 2009-03-03 2014-10-16 Alcon Research, Ltd. Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo
GB0903810D0 (en) 2009-03-05 2009-04-22 Regentec Ltd Delivery system
AU2009342893B2 (en) 2009-03-27 2014-03-06 Australian Nuclear Science And Technology Organisation Triggered release
WO2010114770A1 (en) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
WO2010129545A2 (en) 2009-05-04 2010-11-11 Psivida Us, Inc. Porous silicon drug-eluting particles
CA3149284A1 (en) 2009-12-15 2011-07-14 Incept, Llc Implants and biodegradable fiducial markers
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins PROLONGED DELIVERY OF THERAPEUTIC AGENTS TO AN OCULAR COMPARTMENT
US20130071349A1 (en) 2010-03-02 2013-03-21 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
US9162981B2 (en) 2010-03-23 2015-10-20 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
CA2802733C (en) 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
SI2600930T1 (sl) 2010-08-05 2021-08-31 Forsight Vision4, Inc. Injekcijska naprava za dajanje zdravila
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
EP2629760A4 (en) 2010-10-22 2014-04-02 Bind Therapeutics Inc THERAPEUTIC NANOPARTICLES CONTAINING COPOLYMERS OF HIGH MOLECULAR WEIGHT
AU2011323250B2 (en) 2010-11-05 2015-11-19 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
US9382229B2 (en) 2011-02-15 2016-07-05 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
RU2653439C9 (ru) 2011-05-11 2018-10-16 Апеллис Фармасьютикалс, Инк. Клеточно-реактивные аналоги компстатина, аналоги компстатина длительного действия или аналоги компстатина нацеленного действия и их применение
CN106073986B (zh) 2011-09-14 2019-01-11 弗赛特影像5股份有限公司 治疗患者的眼睛的装置
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
EP3613413A1 (en) 2011-12-05 2020-02-26 Incept, LLC Medical organogel processes and compositions
JP6308679B2 (ja) 2011-12-14 2018-04-11 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜浸透が増強されたかまたは炎症が低減されたナノ粒子
WO2013110028A1 (en) 2012-01-19 2013-07-25 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
HUE050904T2 (hu) 2012-01-23 2021-01-28 Allergan Inc Idõben fokozatos felszabadítású biológiailag lebontható vagy biológiailag erodeálódó mikrogömbök vagy mikrorészecskék, melyek egy megszilárduló depó-képzõ injekciós gyógyszerben vannak szuszpendálva
CA2867381C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
CN104394891B (zh) * 2012-03-16 2019-04-16 约翰霍普金斯大学 用于递送活性剂的非线性多嵌段共聚物-药物结合物
US20140107025A1 (en) 2012-04-16 2014-04-17 Jade Therapeutics, Llc Ocular drug delivery system
NZ742005A (en) 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
CA2872519C (en) 2012-05-04 2017-09-05 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
WO2013177367A2 (en) 2012-05-23 2013-11-28 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
CN104582685A (zh) 2012-06-25 2015-04-29 拜尔健康护理有限责任公司 含有舒尼替尼的局部眼科药物组合物
EA201590586A1 (ru) 2012-09-17 2015-08-31 Бинд Терапьютикс, Инк. Терапевтические наночастицы, включающие терапевтический агент, способы их получения и применения
US9044319B2 (en) 2013-03-01 2015-06-02 Cormatrix Cardiovascular, Inc. Anchored cardiovascular valve
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US9504653B2 (en) 2013-04-01 2016-11-29 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
CN104208715B (zh) 2013-05-31 2016-12-28 天津键凯科技有限公司 具有提高的药物生物活性的低分子量聚乙二醇药物结合物
DK2848262T3 (da) 2013-09-12 2021-02-08 Smartdyelivery Gmbh Cellespecifik målretning ved hjælp af nanostrukturerede bærersystemer
US9655862B2 (en) * 2013-10-29 2017-05-23 Shaker A. Mousa Ocular nanoformulation and method of use in angiogenesis-mediated disorders
ES2826392T3 (es) 2013-11-19 2021-05-18 Univ Cornell Materiales de armazón de tejido para la regeneración de tejido y métodos de fabricación
CA2933900A1 (en) 2013-12-20 2015-06-25 Georgia Tech Research Corporation Formulations and methods for targeted ocular delivery of therapeutic agents
KR101564401B1 (ko) 2014-04-10 2015-11-02 한국화학연구원 브린졸아마이드의 제조방법
ES2964536T3 (es) 2014-05-09 2024-04-08 Univ Yale Partículas recubiertas con poliglicerol hiperramificado y métodos para su preparación
EP3193827A1 (en) 2014-08-13 2017-07-26 The Johns Hopkins University Glucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization
US20160106587A1 (en) 2014-10-16 2016-04-21 Incept, Llc Ocular gels or hydrogels and microinjectors
US10550187B2 (en) 2014-10-24 2020-02-04 Incept, Llc Extra luminal scaffold
AU2015360469B2 (en) 2014-12-10 2021-03-25 Incept, Llc Hydrogel drug delivery implants
EP4445952A2 (en) * 2014-12-15 2024-10-16 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of glaucoma
JP6479485B2 (ja) 2015-01-15 2019-03-06 大内新興化学工業株式会社 眼疾患治療用ナノ粒子製剤
WO2016118506A1 (en) 2015-01-20 2016-07-28 The Johns Hopkins University Compositions for the sustained release of anti-glaucoma agents to control intraocular pressure
US20160317438A1 (en) 2015-04-29 2016-11-03 Psivida Us, Inc. Injectable sustained release intraocular device
CN107530334A (zh) 2015-05-05 2018-01-02 普西维达公司 可注射贮库制剂
EP4279064A3 (en) 2015-05-12 2024-02-28 Incept, LLC Drug delivery from hydrogels
JP2018525078A (ja) 2015-07-22 2018-09-06 インセプト・リミテッド・ライアビリティ・カンパニーＩｎｃｅｐｔ，Ｌｌｃ 被覆された涙点プラグ
EP3352749A4 (en) 2015-09-22 2019-09-04 Graybug Vision, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS
JP2018536484A (ja) 2015-11-25 2018-12-13 インセプト・リミテッド・ライアビリティ・カンパニーＩｎｃｅｐｔ，Ｌｌｃ 形状変化する薬物送達デバイス及び方法
RU2019133337A (ru) 2017-03-23 2021-04-23 Грейбуг Вижн, Инк. Лекарственные средства и композиции для лечения глазных нарушений
CA3083805A1 (en) 2017-12-14 2019-06-20 Graybug Vision, Inc. Drugs and compositions for ocular delivery
JP2021522224A (ja) 2018-04-23 2021-08-30 グレイバグ ビジョン インコーポレイテッド 改善された連続式のマイクロ粒子の製造
WO2019210215A1 (en) 2018-04-26 2019-10-31 Graybug Vision, Inc. Drugs to treat ocular disorders
TW202035364A (zh) 2018-09-27 2020-10-01 美商灰色視覺公司 用於眼部遞送之化合物及組合物
WO2020102758A1 (en) 2018-11-15 2020-05-22 Graybug Vision, Inc. Improved aggregated microparticles

Also Published As

Publication number Publication date
US10441548B2 (en) 2019-10-15
CN114469872A (zh) 2022-05-13
KR20180102069A (ko) 2018-09-14
US20240041783A1 (en) 2024-02-08
CN108367079A (zh) 2018-08-03
AU2016353355A1 (en) 2018-05-17
IL259167A (en) 2018-06-28
EA038755B1 (ru) 2021-10-14
WO2017083779A1 (en) 2017-05-18
US20200000734A1 (en) 2020-01-02
CN108367079B (zh) 2022-11-22
AU2016353355B2 (en) 2022-09-15
US11564890B2 (en) 2023-01-31
CA3004886A1 (en) 2017-05-18
MX2018005932A (es) 2019-05-20
JP2023052493A (ja) 2023-04-11
EP3373978A4 (en) 2019-06-26
AU2016353355B9 (en) 2022-09-29
EA201891147A1 (ru) 2018-10-31
US20170135960A1 (en) 2017-05-18
US20200000735A1 (en) 2020-01-02
EP3373978A1 (en) 2018-09-19
BR112018009644A2 (pt) 2018-11-06
SG11201803663XA (en) 2018-05-30
PH12018500905A1 (en) 2018-11-05
JP2018533596A (ja) 2018-11-15
US11331276B2 (en) 2022-05-17

Similar Documents

Publication Publication Date Title
HK1257499A1 (zh) 用於治療的聚集性微粒
PT3132034T (pt) Terapêutica
GB2538731B (en) Methods
ZA201706362B (en) Microparticles
GB201512365D0 (en) Novel therapy
HK1243598A1 (zh) 聯合治療
GB201518762D0 (en) Methods
GB201410216D0 (en) Therapeutic
GB201508927D0 (en) Methods
GB201515655D0 (en) Methods
GB201510637D0 (en) Therapeutic
GB201601250D0 (en) No details present
GB2525074B (en) Radiotherapy system
GB201505382D0 (en) Novel therapy
IL241947A (en) Attach multiple requests
GB201516068D0 (en) Novel therapy
GB201512609D0 (en) Methods
ZA201604189B (en) Chute
GB201518805D0 (en) Therapy
GB201521339D0 (en) Methods
GB201510756D0 (en) Methods
GB201509909D0 (en) Methods
GB201509813D0 (en) Methods
GB201509696D0 (en) Methods
GB201510707D0 (en) Solariums